Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Definium Therapeutics ( (DFTX) ) has issued an announcement.
On May 19, 2026, Definium Therapeutics, Inc. reported that it had updated its corporate presentation to highlight a late-stage pipeline centered on DT120 oral disintegrating tablet, its lead program in five Phase 3 studies across generalized anxiety disorder and major depressive disorder, as well as additional development in posttraumatic stress disorder and other potential indications. The company underscored its experienced management team, strong cash position of $373.4 million as of March 31, 2026, and anticipated three Phase 3 readouts in 2026 that it believes could support billion-dollar commercial opportunities in psychiatric indications, reinforcing its positioning in the emerging psychedelics-inspired medicines segment while operating strictly within regulated laboratory and clinical settings.
Definium also emphasized DT402, its proprietary R(-)-MDMA program in development for autism spectrum disorder, alongside a stated focus on securing and maintaining robust intellectual property protection and complying with stringent U.S. controlled substances regulations. The updated presentation reiterated that the company does not engage in any illegal production or distribution of psychedelic or hallucinogenic substances, and that its products will only be commercialized following successful clinical evidence of safety and efficacy and subsequent regulatory approval, framing its pipeline as part of a broader push to establish psychedelics-based therapies within mainstream psychiatry under approved regulatory frameworks.
The most recent analyst rating on (DFTX) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Definium Therapeutics stock, see the DFTX Stock Forecast page.
Spark’s Take on DFTX Stock
According to Spark, TipRanks’ AI Analyst, DFTX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large losses, and sustained cash burn), partially offset by a debt-free balance sheet. Technicals are moderately supportive with the stock above key longer-term moving averages, and the latest earnings call adds upside optionality from near-term Phase III readouts and a strong cash runway, though elevated spending and execution/regulatory risks remain meaningful.
To see Spark’s full report on DFTX stock, click here.
More about Definium Therapeutics
Definium Therapeutics, Inc. is a neuro-pharmaceutical drug development company focused on central nervous system disorders, with a strategic emphasis on generalized anxiety disorder and major depressive disorder. Its lead candidate is DT120 oral disintegrating tablet, a proprietary, pharmaceutically optimized form of lysergide tartrate, supported by comprehensive intellectual property covering formulation, manufacturing, and treatment methods, and a late-stage pipeline that also includes DT402, a proprietary R(-)-MDMA candidate targeting autism spectrum disorder.
Average Trading Volume: 1,738,659
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.29B
Find detailed analytics on DFTX stock on TipRanks’ Stock Analysis page.